ACAyden Case

Ayden Case

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Ayden Case has a total of 44 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Sp1 links CD46 to CD4 T cell metabolic fitness, survival, and retroviral control

    by Parul Singh, Luopin Wang, Pavitra Ramdas, Shyaman M. Jayasundara, Gaelle Le Friec, Natalia Kunz, Prakriti Mudvari, Erin E. West, Ayden Case, Nicolas S. Merle, et al.

    CD46, a human-specific complement receptor, regulates gene programs essential for T helper 1 (T H 1) cell differentiation, yet how it exerts direct transcriptional control remains unclear. We show that the CD46 signaling domain cytoplasmic tail 1 (CYT-1) engages the transcription factor Sp1 in human CD4 T cells to dynamically modulate Sp1-DNA interactions. Beyond promoting T H 1 cell induction, CD46-Sp1–controlled programs support naive CD4 T cell survival by maintaining nutrient transporter expression and suppressing the intrinsic caspase 9–caspase 3 apoptotic pathway. The CD46-Sp1 axis also restrains HIV transcription in infected CD4 T cells in vitro. Disruption of CYT-1–Sp1–regulated programs identifies T cells from individuals with HIV who exhibit incomplete viral suppression during antiretroviral therapy. Together, these findings define a human-specific transcriptional mechanism linking complement signaling to metabolic adaptation, apoptosis regulation, and antiviral defense, highlighting an unexpected role for CD46 in coordinating T cell homeostasis and host protection.

  • Open Access

    Fluorescence-Activated Cell Sorting Depletes Macrophages and Triggers Inflammation in the Single-Cell Immune Landscape of Human Atherosclerosis

    by Ayden G. Case, James W. O’bRien, Fiona T.W. Charlier, Ali B.A.K. Al-Hadithi, Mohammed M. Chowdhury, Stephen A. Newland, Zixuan Huang, Gemma Basatemur, Xiaohui Zhao, Ayoola I. Awopetu, et al.


  • Open Access

    Low-dose interleukin-2 induces clonal expansion of BACH2-repressed effector regulatory T cells following acute coronary syndrome

    by A. G. Case, J. W. O’bRien, Y. Lu, F. T. W. Charlier, X. Zhao, Y. Weng, L. Masters, Z. K. Tuong, R. Sriranjan, J. Cheriyan, et al.

    Targeting inflammation in atherosclerotic cardiovascular disease remains a major unmet need. Low-dose interleukin-2 (IL-2LD) selectively increases regulatory T (Treg) cell numbers in patients with coronary artery disease. Here we combine single-cell transcriptomics and T cell receptor analyses and show that IL-2LD clonally expands effector Treg cells in patients with acute coronary syndromes. The clonally expanded Treg cells upregulate key immunosuppressive and metabolic pathways and show an increased number of predicted ligand–receptor interactions. These Treg cells also display similar predicted antigen specificities, which cluster with published sequences specific to atherosclerotic cardiovascular disease. By tracking the T cell receptors of single cells over time, we identify an inflammatory polarization of the T cell compartment after myocardial infarction, which is restrained by IL-2LD. We identify BACH2 as a repressor of the Treg effector program. However, BACH2-mediated regulation is bypassed with IL-2LD. Overall, these results lend insight into the IL-2-driven clonal expansion program in human Treg cells, with important therapeutic implications for patients with cardiovascular and other immune-mediated diseases.


  • Open Access

    Therapeutic Avenues to Modulate B-Cell Function in Patients With Cardiovascular Disease

    by James W. O’bRien, Ayden Case, Claudia Kemper, Tian X. Zhao, Ziad Mallat

    The adaptive immune system plays an important role in the development and progression of atherosclerotic cardiovascular disease. B cells can have both proatherogenic and atheroprotective roles, making treatments aimed at modulating B cells important therapeutic targets. The innate-like B-cell response is generally considered atheroprotective, while the adaptive response is associated with mixed consequences for atherosclerosis. Additionally, interactions of B cells with components of the adaptive and innate immune system, including T cells and complement, also represent key points for therapeutic regulation. In this review, we discuss therapeutic approaches based on B-cell depletion, modulation of B-cell survival, manipulation of both the antibody-dependent and antibody-independent B-cell response, and emerging immunization techniques.


  • Top Cited Papers

    Canonical and non-canonical roles of complement in atherosclerosis

    by Pasquale Maffia, Claudio Mauro, Ayden Case, Claudia Kemper

    Cardiovascular diseases are the leading cause of death globally, and atherosclerosis is the major contributor to the development and progression of cardiovascular diseases. Immune responses have a central role in the pathogenesis of atherosclerosis, with the complement system being an acknowledged contributor. Chronic activation of liver-derived and serum-circulating canonical complement sustains endothelial inflammation and innate immune cell activation, and deposition of complement activation fragments on inflamed endothelial cells is a hallmark of atherosclerotic plaques. However, increasing evidence indicates that liver-independent, cell-autonomous and non-canonical complement activities are underappreciated contributors to atherosclerosis. Furthermore, complement activation can also have atheroprotective properties. These specific detrimental or beneficial contributions of the complement system to the pathogenesis of atherosclerosis are dictated by the location of complement activation and engagement of its canonical versus non-canonical functions in a temporal fashion during atherosclerosis progression. In this Review, we summarize the classical and the emerging non-classical roles of the complement system in the pathogenesis of atherosclerosis and discuss potential strategies for therapeutic modulation of complement for the prevention and treatment of atherosclerotic cardiovascular disease.